Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out

IUBMB Life

Volumn 67, Issue 6, 2015, Pages 404-413

  Chen, John J ^a   Genereux, Joseph C ^a   Wiseman, R Luke ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

chaperones; protein folding; stress activated signaling

Indexed keywords

AMYLOID PROTEIN;

AMYLOIDOSIS; ENDOPLASMIC RETICULUM; HUMAN; METABOLISM; PATHOLOGY; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN TRANSPORT; SECRETION (PROCESS); SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; ENDOPLASMIC RETICULUM; HUMANS; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

EID: 84934282201     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1386     Document Type: Review

References (79)

1. Blancas-Mejia, L. M., and, Ramirez-Alvarado, M., (2013) Systemic amyloidoses. Annu. Rev. Biochem. 82, 745-774.
2. Gillmore, J. D., and, Hawkins, P. N., (2013) Pathophysiology and treatment of systemic amyloidosis. Nat. Rev. Nephrol. 9, 574-586.
3. Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S., Merlini, G., et al., (2014) Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21, 221-224.
4. Holmgren, G., Ericzon, B. G., Groth, C. G., Steen, L., Suhr, O., et al., (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341, 1113-1116.
5. Suhr, O. B., Herlenius, G., Friman, S., and, Ericzon, B. G., (2000) Liver transplantation for hereditary transthyretin amyloidosis. Liver Transpl. 6, 263-276.
6. Gillmore, J. D., Stangou, A. J., Lachmann, H. J., Goodman, H. J., Wechalekar, A. D., et al., (2006) Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am. J. Transplant. 6, 2342-2347.
7. Gillmore, J. D., Lachmann, H. J., Rowczenio, D., Gilbertson, J. A., Zeng, C. H., et al., (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A α-chain amyloidosis. J. Am. Soc. Nephrol. 20, 444-451.
8. Merlini, G., Seldin, D. C., and, Gertz, M. A., (2011) Amyloidosis: pathogenesis and new therapeutic options. J. Clin. Oncol. 29, 1924-1933.
9. Merlini, G., Comenzo, R. L., Seldin, D. C., Wechalekar, A., and, Gertz, M. A., (2014) Immunoglobulin light chain amyloidosis. Expert Rev. Hematol. 7, 143-156.
10. Bulawa, C. E., Connelly, S., Devit, M., Wang, L., Weigel, C., et al., (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. USA 109, 9629-9634.
11. Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Plante-Bordeneuve, V., et al., (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79, 785-792.
12. Coelho, T., Maia, L. F., da Silva, A. M., Cruz, M. W., Plante-Bordeneuve, V., et al., (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J. Neurol. 260, 2802-2814.
13. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., et al., (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
14. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W., and, Buxbaum, J. N., (2004) Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA 101, 2817-2822.
15. Haass, C., and, Selkoe, D. J., (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
16. Lashuel, H. A., Overk, C. R., Oueslati, A., and, Masliah, E., (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38-48.
17. Adams, D., Lozeron, P., and, Lacroix, C., (2012) Amyloid neuropathies. Curr. Opin. Neurol. 25, 564-572.
18. Obici, L., and, Merlini, G., (2014) An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin. Investig. Drugs 23, 1239-1251.
19. Castano, A., Drachman, B. M., Judge, D., and, Maurer, M. S., (2015) Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail. Rev. 20, 163-178.
20. Braakman, I., and, Bulleid, N. J., (2011) Protein folding and modification in the mammalian endoplasmic reticulum. Annu. Rev. Biochem. 80, 71-99.
21. Smith, M. H., Ploegh, H. L., and, Weissman, J. S., (2011) Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science 334, 1086-1090.
22. Guerriero, C. J., and, Brodsky, J. L., (2012) The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. Physiol. Rev. 92, 537-576.
23. Kruse, K. B., Brodsky, J. L., and, McCracken, A. A., (2006) Autophagy: an ER protein quality control process. Autophagy 2, 135-137.
24. Wiseman, R. L., Powers, E. T., Buxbaum, J. N., Kelly, J. W., and, Balch, W. E., (2007) An adaptable standard for protein export from the endoplasmic reticulum. Cell 131, 809-821.
25. Sekijima, Y., Wiseman, R. L., Matteson, J., Hammarstrom, P., Miller, S. R., et al., (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121, 73-85.
26. Kumita, J. R., Johnson, R. J., Alcocer, M. J., Dumoulin, M., Holmqvist, F., et al., (2006) Impact of the native-state stability of human lysozyme variants on protein secretion by Pichia pastoris. FEBS J. 273, 711-720.
27. Ron, D., and, Walter, P., (2007) Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519-529.
28. Walter, P., and, Ron, D., (2011) The unfolded protein response: from stress pathway to homeostatic regulation. Science 334, 1081-1086.
29. Wang, S., and, Kaufman, R. J., (2012) The impact of the unfolded protein response on human disease. J. Cell Biol. 197, 857-867.
30. Wiseman, R. L., Koulov, A., Powers, E., Kelly, J. W., and, Balch, W. E., (2007) Protein energetics in maturation of the early secretory pathway. Curr. Opin. Cell Biol. 19, 359-367.
31. Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., and, Balch, W. E., (2009) Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959-991.
32. Calamini, B., and, Morimoto, R. I., (2012) Protein homeostasis as a therapeutic target for diseases of protein conformation. Curr. Top. Med. Chem. 12, 2623-2640.
33. Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., et al., (2003) An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11, 619-633.
34. Lu, P. D., Jousse, C., Marciniak, S. J., Zhang, Y., Novoa, I., et al., (2004) Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J. 23, 169-179.
35. Novoa, I., Zeng, H., Harding, H. P., and, Ron, D., (2001) Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2α. J. Cell Biol. 153, 1011-1022.
36. Ma, Y., and, Hendershot, L. M., (2003) Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J. Biol. Chem. 278, 34864-34873.
37. Tabas, I., and, Ron, D., (2011) Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13, 184-190.
38. Urra, H., Dufey, E., Lisbona, F., Rojas-Rivera, D., and, Hetz, C., (2013) When ER stress reaches a dead end. Biochim. Biophys. Acta 1833, 3507-3517.
39. Wek, R. C., Jiang, H. Y., and, Anthony, T. G., (2006) Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans. 34, 7-11.
40. Sonenberg, N., and, Hinnebusch, A. G., (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731-745.
41. Jurkin, J., Henkel, T., Nielsen, A. F., Minnich, M., Popow, J., et al., (2014) The mammalian tRNA ligase complex mediates splicing of XBP1 mRNA and controls antibody secretion in plasma cells. EMBO J. 33, 2922-2936.
42. Kosmaczewski, S. G., Edwards, T. J., Han, S. M., Eckwahl, M. J., Meyer, B. I., et al., (2014) The RtcB RNA ligase is an essential component of the metazoan unfolded protein response. EMBO Rep. 15, 1278-1285.
43. Lu, Y., Liang, F. X., and, Wang, X., (2014) A synthetic biology approach identifies the mammalian UPR RNA ligase RtcB. Mol. Cell 55, 758-770.
44. Lee, A. H., Iwakoshi, N. N., and, Glimcher, L. H., (2003) XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol. Cell. Biol. 23, 7448-7459.
45. Yamamoto, K., Yoshida, H., Kokame, K., Kaufman, R. J., and, Mori, K., (2004) Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-II. J. Biochem. 136, 343-350.
46. Shoulders, M. D., Ryno, L. M., Genereux, J. C., Moresco, J. J., Tu, P. G., et al., (2013) Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep. 3, 1279-1292.
47. Hollien, J., and, Weissman, J. S., (2006) Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 313, 104-107.
48. Han, D., Lerner, A. G., Vande Walle, L., Upton, J. P., Xu, W., et al., (2009) IRE1α kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 138, 562-575.
49. Hollien, J., Lin, J. H., Li, H., Stevens, N., Walter, P., et al., (2009) Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J. Cell Biol. 186, 323-331.
50. Gaddam, D., Stevens, N., and, Hollien, J., (2013) Comparison of mRNA localization and regulation during endoplasmic reticulum stress in Drosophila cells. Mol. Biol. Cell 24, 14-20.
51. Maurel, M., Chevet, E., Tavernier, J., and, Gerlo, S., (2014) Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem. Sci. 39, 245-254.
52. Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., et al., (2000) Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664-666.
53. Nadanaka, S., Okada, T., Yoshida, H., and, Mori, K., (2007) Role of disulfide bridges formed in the luminal domain of ATF6 in sensing endoplasmic reticulum stress. Mol. Cell. Biol. 27, 1027-1043.
54. Johnson, S. M., Connelly, S., Fearns, C., Powers, E. T., and, Kelly, J. W., (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J. Mol. Biol. 421, 185-203.
55. Buxbaum, J. N., (2004) The systemic amyloidoses. Curr. Opin. Rheumatol. 16, 67-75.
56. Garzuly, F., Vidal, R., Wisniewski, T., Brittig, F., and, Budka, H., (1996) Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly). Neurology 47, 1562-1567.
57. Hammarstrom, P., Sekijima, Y., White, J. T., Wiseman, R. L., Lim, A., et al., (2003) D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 42, 6656-6663.
58. Sekijima, Y., Hammarstrom, P., Matsumura, M., Shimizu, Y., Iwata, M., et al., (2003) Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab. Invest. 83, 409-417.
59. Sato, T., Susuki, S., Suico, M. A., Miyata, M., Ando, Y., et al., (2007) Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J. 26, 2501-2512.
60. Chen, J. J., Genereux, J. C., Qu, S., Hulleman, J. D., Shoulders, M. D., et al., (2014) ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein. Chem. Biol. 21, 1564-1574.
61. Jacobson, D. R., McFarlin, D. E., Kane, I., and, Buxbaum, J. N., (1992) Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum. Genet. 89, 353-356.
62. Ryno, L. M., Wiseman, R. L., and, Kelly, J. W., (2013) Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. Curr. Opin. Chem. Biol. 17, 346-352.
63. Buxbaum, J. N., Tagoe, C., Gallo, G., Walker, J. R., Kurian, S., et al., (2012) Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?. FASEB J 12, 2283-2293
64. Norgren, N., Olsson, M., Nystrom, H., Ericzon, B. G., de Tayrac, M., et al., (2014) Gene expression profile in hereditary transthyretin amyloidosis: differences in targeted and source organs. Amyloid 21, 113-119.
65. Stangou, A. J., Heaton, N. D., and, Hawkins, P. N., (2005) Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N. Engl. J. Med. 352, 2356.
66. Goto, T., Yamashita, T., Ueda, M., Ohshima, S., Yoneyama, K., et al., (2006) Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am. J. Transplant. 6, 2512-2515.
67. Takei, Y., Gono, T., Yazaki, M., Ikeda, S., Ikegami, T., et al., (2007) Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl. 13, 215-218.
68. Llado, L., Baliellas, C., Casasnovas, C., Ferrer, I., Fabregat, J., et al., (2010) Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl. 16, 1386-1392.
69. Naidoo, N., (2009) ER and aging-protein folding and the ER stress response. Ageing Res. Rev. 8, 150-159.
70. Lindquist, S. L., and, Kelly, J. W., (2011) Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb. Perspect. Biol. 3. pii: a004507.
71. Kumita, J. R., Helmfors, L., Williams, J., Luheshi, L. M., Menzer, L., et al., (2012) Disease-related amyloidogenic variants of human lysozyme trigger the unfolded protein response and disturb eye development in Drosophila melanogaster. FASEB J. 26, 192-202.
72. Kamada, Y., Kusakabe, T., and, Sugimoto, Y., (2015) Amyloidogenic lysozymes accumulate in the endoplasmic reticulum accompanied by the augmentation of ER stress signals. Biochim. Biophys. Acta 1850, 1107-1119.
73. Cooley, C. B., Ryno, L. M., Plate, L., Morgan, G. J., Hulleman, J. D., et al., (2014) Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc. Natl. Acad. Sci. USA 111, 13046-13051.
74. Smith, S. E., Granell, S., Salcedo-Sicilia, L., Baldini, G., Egea, G., et al., (2011) Activating transcription factor 6 limits intracellular accumulation of mutant α(1)-antitrypsin Z and mitochondrial damage in hepatoma cells. J. Biol. Chem. 286, 41563-41577.
75. Chiang, W. C., Hiramatsu, N., Messah, C., Kroeger, H., and, Lin, J. H., (2012) Selective activation of ATF6 and PERK endoplasmic reticulum stress signaling pathways prevent mutant rhodopsin accumulation. Invest. Ophthalmol. Vis. Sci. 53, 7159-7166.
76. Chiang, W. C., Messah, C., and, Lin, J. H., (2012) IRE1 directs proteasomal and lysosomal degradation of misfolded rhodopsin. Mol. Biol. Cell 23, 758-770.
77. Korennykh, A. V., Egea, P. F., Korostelev, A. A., Finer-Moore, J., Zhang, C., et al., (2009) The unfolded protein response signals through high-order assembly of Ire1. Nature 457, 687-693.
78. Kudo, T., Kanemoto, S., Hara, H., Morimoto, N., Morihara, T., et al., (2008) A molecular chaperone inducer protects neurons from ER stress. Cell Death Differ. 15, 364-375.
79. Howarth, D. L., Lindtner, C., Vacaru, A. M., Sachidanandam, R., Tsedensodnom, O., et al., (2014) Activating transcription factor 6 is necessary and sufficient for alcoholic fatty liver disease in zebrafish. PLoS Genet. 10, e1004335.